<?xml version="1.0" encoding="UTF-8" ?><xml><records><record><database name="Round 2 publications.enl" path="C:\downloads\Round 2 publications.enl">Round 2 publications.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>1392</rec-number><foreign-keys><key app="EN" db-id="0e0ee20tl9f50te0zeoxeaxnps5s0xd9dz5e">1392</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Yang, M.</author><author>Cheng, K.</author><author>Qi, S.</author><author>Liu, H.</author><author>Jiang, Y.</author><author>Jiang, H.</author><author>Li, J.</author><author>Chen, K.</author><author>Zhang, H.</author><author>Cheng, Z.</author></authors></contributors><auth-address>Department of Diagnostic Ultrasound, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing 100730, China.</auth-address><titles><title>Affibody modified and radiolabeled gold-Iron oxide hetero-nanostructures for tumor PET, optical and MR imaging</title><secondary-title>Biomaterials</secondary-title><alt-title>Biomaterials</alt-title></titles><periodical><full-title>Biomaterials</full-title><abbr-1>Biomaterials</abbr-1></periodical><alt-periodical><full-title>Biomaterials</full-title><abbr-1>Biomaterials</abbr-1></alt-periodical><pages>2796-806</pages><volume>34</volume><number>11</number><keywords><keyword>CA151459</keyword></keywords><dates><year>2013</year><pub-dates><date>Apr</date></pub-dates></dates><isbn>1878-5905 (Electronic)&#xD;0142-9612 (Linking)</isbn><accession-num>23343632</accession-num><abstract>A highly monodispersed hetero-nanostructure with two different functional nanomaterials (gold (Au) and iron oxide (Fe(3)O(4,) IO)) within one structure was successfully developed as Affibody based trimodality nanoprobe (positron emission tomography, PET; optical imaging; and magnetic resonance imaging, MRI) for imaging of epidermal growth factor receptor (EGFR) positive tumors. Unlike other regular nanostructures with a single component, the Au-IO hetero-nanostructures (Au-IONPs) with unique chemical and physical properties have capability to combine several imaging modalities together to provide complementary information. The IO component within hetero-nanostructures serve as a T(2) reporter for MRI; and gold component serve as both optical and PET reporters. Moreover, such hetero-nanoprobes could provide a robust nano-platform for surface-specific modification with both targeting molecules (anti-EGFR Affibody protein) and PET imaging reporters (radiometal (64)Cu chelators) in highly efficient and reliable manner. In vitro and in vivo study showed that the resultant nanoprobe provided high specificity, sensitivity, and excellent tumor contrast for both PET and MRI imaging in the human EGFR-expressing cells and tumors. Our study data also highlighted the EGFR targeting efficiency of hetero-nanoparticles and the feasibility for their further theranostic applications.</abstract><notes>CA151459/CA/NCI NIH HHS/United States&#xD;U54 CA119367/CA/NCI NIH HHS/United States&#xD;U54 CA119367/CA/NCI NIH HHS/United States&#xD;U54 CA151459/CA/NCI NIH HHS/United States&#xD;Journal Article&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;Netherlands</notes><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=23343632 </url></related-urls></urls><language>eng</language></record><record><database name="Round 2 publications.enl" path="C:\downloads\Round 2 publications.enl">Round 2 publications.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>1404</rec-number><foreign-keys><key app="EN" db-id="0e0ee20tl9f50te0zeoxeaxnps5s0xd9dz5e">1404</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Yang, D.</author><author>Sun, Y.</author><author>Hu, L.</author><author>Zheng, H.</author><author>Ji, P.</author><author>Pecot, C. V.</author><author>Zhao, Y.</author><author>Reynolds, S.</author><author>Cheng, H.</author><author>Rupaimoole, R.</author><author>Cogdell, D.</author><author>Nykter, M.</author><author>Broaddus, R.</author><author>Rodriguez-Aguayo, C.</author><author>Lopez-Berestein, G.</author><author>Liu, J.</author><author>Shmulevich, I.</author><author>Sood, A. K.</author><author>Chen, K.</author><author>Zhang, W.</author></authors></contributors><auth-address>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.</auth-address><titles><title>Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer</title><secondary-title>Cancer Cell</secondary-title><alt-title>Cancer cell</alt-title></titles><periodical><full-title>Cancer Cell</full-title><abbr-1>Cancer cell</abbr-1></periodical><alt-periodical><full-title>Cancer Cell</full-title><abbr-1>Cancer cell</abbr-1></alt-periodical><pages>186-99</pages><volume>23</volume><number>2</number><keywords><keyword>CA151668</keyword><keyword>Animals</keyword><keyword>Apoptosis/drug effects</keyword><keyword>Blotting, Western</keyword><keyword>Cadherins/genetics/metabolism</keyword><keyword>Cell Movement</keyword><keyword>Cell Proliferation/drug effects</keyword><keyword>Cystadenocarcinoma, Serous/*genetics/mortality/pathology</keyword><keyword>Epithelial-Mesenchymal Transition/*genetics</keyword><keyword>Female</keyword><keyword>Gene Expression Profiling</keyword><keyword>*Gene Expression Regulation, Neoplastic</keyword><keyword>Humans</keyword><keyword>Immunoenzyme Techniques</keyword><keyword>Mesoderm/metabolism/*pathology</keyword><keyword>Mice</keyword><keyword>Mice, Nude</keyword><keyword>MicroRNAs/*genetics</keyword><keyword>Middle Aged</keyword><keyword>Neoplasm Grading</keyword><keyword>Ovarian Neoplasms/*genetics/mortality/pathology</keyword><keyword>Prognosis</keyword><keyword>RNA, Messenger/genetics</keyword><keyword>Real-Time Polymerase Chain Reaction</keyword><keyword>Reverse Transcriptase Polymerase Chain Reaction</keyword><keyword>Survival Rate</keyword><keyword>Transcription Factors/genetics/metabolism</keyword><keyword>Transforming Growth Factor beta/genetics/metabolism</keyword><keyword>Tumor Cells, Cultured</keyword><keyword>Tumor Markers, Biological/*genetics</keyword><keyword>Vimentin/genetics/metabolism</keyword></keywords><dates><year>2013</year><pub-dates><date>Feb 11</date></pub-dates></dates><isbn>1878-3686 (Electronic)&#xD;1535-6108 (Linking)</isbn><accession-num>23410973</accession-num><abstract>Integrated genomic analyses revealed a miRNA-regulatory network that further defined a robust integrated mesenchymal subtype associated with poor overall survival in 459 cases of serous ovarian cancer (OvCa) from The Cancer Genome Atlas and 560 cases from independent cohorts. Eight key miRNAs, including miR-506, miR-141, and miR-200a, were predicted to regulate 89% of the targets in this network. Follow-up functional experiments illustrate that miR-506 augmented E-cadherin expression, inhibited cell migration and invasion, and prevented TGFbeta-induced epithelial-mesenchymal transition by targeting SNAI2, a transcriptional repressor of E-cadherin. In human OvCa, miR-506 expression was correlated with decreased SNAI2 and VIM, elevated E-cadherin, and beneficial prognosis. Nanoparticle delivery of miR-506 in orthotopic OvCa mouse models led to E-cadherin induction and reduced tumor growth.</abstract><notes>CA016672/CA/NCI NIH HHS/United States&#xD;P50 CA083639/CA/NCI NIH HHS/United States&#xD;P50 CA083639/CA/NCI NIH HHS/United States&#xD;R01 CA109298/CA/NCI NIH HHS/United States&#xD;U24CA143835/CA/NCI NIH HHS/United States&#xD;U54 CA151668/CA/NCI NIH HHS/United States&#xD;U54 CA151668/CA/NCI NIH HHS/United States&#xD;Journal Article&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States</notes><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=23410973 </url></related-urls></urls><language>eng</language></record><record><database name="Round 2 publications.enl" path="C:\downloads\Round 2 publications.enl">Round 2 publications.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>1411</rec-number><foreign-keys><key app="EN" db-id="0e0ee20tl9f50te0zeoxeaxnps5s0xd9dz5e">1411</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Xu, R.</author><author>Huang, Y.</author><author>Mai, J.</author><author>Zhang, G.</author><author>Guo, X.</author><author>Xia, X.</author><author>Koay, E. J.</author><author>Qin, G.</author><author>Erm, D. R.</author><author>Li, Q.</author><author>Liu, X.</author><author>Ferrari, M.</author><author>Shen, H.</author></authors></contributors><auth-address>Department of Nanomedicine, The Methodist Hospital Research Institute, 6670 Bertner Avenue, Houston, Texas 77030, USA.</auth-address><titles><title>Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy</title><secondary-title>Small</secondary-title><alt-title>Small (Weinheim an der Bergstrasse, Germany)</alt-title></titles><periodical><full-title>Small</full-title><abbr-1>Small (Weinheim an der Bergstrasse, Germany)</abbr-1></periodical><alt-periodical><full-title>Small</full-title><abbr-1>Small (Weinheim an der Bergstrasse, Germany)</abbr-1></alt-periodical><pages>1799-808</pages><volume>9</volume><number>9-10</number><keywords><keyword>Ca151668</keyword></keywords><dates><year>2013</year><pub-dates><date>May 27</date></pub-dates></dates><isbn>1613-6829 (Electronic)&#xD;1613-6810 (Linking)</isbn><accession-num>23293085</accession-num><abstract>The ataxia-telangiectasia mutated (ATM) protein plays a central role in DNA damage response and cell cycle checkpoints, and may be a promising target for cancer therapy if normal tissue toxicity could be avoided. The strategy presented here to target ATM for breast cancer therapy involves the use of liposomal-encapsulated, gene-specific ATM siRNA delivered with a well-characterized porous silicon-based multistage vector (MSV) delivery system (MSV/ATM). Biweekly treatment of MSV/ATM suppressed ATM expression in tumor tissues, and consequently inhibited growth of MDA-MB-231 orthotopic tumor in nude mice. At the therapeutic dosage, neither free liposomal ATM siRNA nor MSV/ATM triggered an acute immune response in BALB/c mice, including changes in serum cytokines, chemokines or colony-stimulating factors. Weekly treatments of mice with free liposomal ATM siRNA or MSV/ATM for 4 weeks did not cause significant changes in body weight, hematology, blood biochemistry, or major organ histology. These results indicate that MSV/ATM is biocompatible and efficacious in inhibiting tumor growth, and that further preclinical evaluation is warranted for the development of MSV/ATM as a potential therapeutic agent.</abstract><notes>U54CA143837/CA/NCI NIH HHS/United States&#xD;U54CA151668/CA/NCI NIH HHS/United States&#xD;Journal Article&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Research Support, U.S. Gov&apos;t, Non-P.H.S.&#xD;Germany</notes><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=23293085 </url></related-urls></urls><language>eng</language></record><record><database name="Round 2 publications.enl" path="C:\downloads\Round 2 publications.enl">Round 2 publications.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>1374</rec-number><foreign-keys><key app="EN" db-id="0e0ee20tl9f50te0zeoxeaxnps5s0xd9dz5e">1374</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Werner, M. E.</author><author>Cummings, N. D.</author><author>Sethi, M.</author><author>Wang, E. C.</author><author>Sukumar, R.</author><author>Moore, D. T.</author><author>Wang, A. Z.</author></authors></contributors><auth-address>Laboratory of Nano- and Translational Medicine, Department of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA.</auth-address><titles><title>Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer</title><secondary-title>Int J Radiat Oncol Biol Phys</secondary-title><alt-title>International journal of radiation oncology, biology, physics</alt-title></titles><periodical><full-title>Int J Radiat Oncol Biol Phys</full-title><abbr-1>International journal of radiation oncology, biology, physics</abbr-1></periodical><alt-periodical><full-title>Int J Radiat Oncol Biol Phys</full-title><abbr-1>International journal of radiation oncology, biology, physics</abbr-1></alt-periodical><pages>463-8</pages><volume>86</volume><number>3</number><keywords><keyword>CA151652</keyword></keywords><dates><year>2013</year><pub-dates><date>Jul 1</date></pub-dates></dates><isbn>1879-355X (Electronic)&#xD;0360-3016 (Linking)</isbn><accession-num>23708084</accession-num><abstract>PURPOSE: A key research objective in radiation oncology is to identify agents that can improve chemoradiation therapy. Nanoparticle (NP) chemotherapeutics possess several properties, such as preferential accumulation in tumors, that are uniquely suited for chemoradiation therapy. To facilitate the clinical translation of NP chemotherapeutics in chemoradiation therapy, we conducted preclinical evaluation of Genexol-PM, the only clinically approved NP chemotherapeutic with a controlled drug release profile, as a radiosensitizer using non-small cell lung cancer (NSCLC) as a model disease. METHODS AND MATERIALS: The physical characteristics and drug release profile of Genexol-PM were characterized. Genexol-PM&apos;s efficacy as a radiosensitizer was evaluated in vitro using NSCLC cell lines and in vivo using mouse xenograft models of NSCLC. Paclitaxel dose to normal lung and liver after Genexol-PM administration were quantified and compared with that after Taxol administration. RESULTS: Genexol-PM has a size of 23.91 +/- 0.41 nm and surface charge of -8.1 +/- 3.1 mV. It releases paclitaxel in a controlled release profile. In vitro evaluation of Genexol-PM as a radiosensitizer showed it is an effective radiosensitizer and is more effective than Taxol, its small molecule counterpart, at the half maximal inhibitory concentration. In vivo study of Genexol-PM as a radiosensitizer demonstrated that it is more effective as a radiosensitizer than Taxol. We also found that Genexol-PM leads to lower paclitaxel exposure to normal lung tissue than Taxol at 6 hours postadministration. CONCLUSIONS: We have demonstrated that Genexol-PM is more effective than Taxol as a radiosensitizer in the preclinical setting and holds high potential for clinical translation. Our data support the clinical evaluation of Genexol-PM in chemoradiation therapy for NSCLC.</abstract><notes>1-U54-CA151652-01/CA/NCI NIH HHS/United States&#xD;5-K12-CA120780-01-05/CA/NCI NIH HHS/United States&#xD;K12 CA120780/CA/NCI NIH HHS/United States&#xD;U54 CA151652/CA/NCI NIH HHS/United States&#xD;Journal Article&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States</notes><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=23708084 </url></related-urls></urls><language>eng</language></record><record><database name="Round 2 publications.enl" path="C:\downloads\Round 2 publications.enl">Round 2 publications.enl</database><source-app name="EndNote" version="17.0">EndNote</source-app><rec-number>1380</rec-number><foreign-keys><key app="EN" db-id="0e0ee20tl9f50te0zeoxeaxnps5s0xd9dz5e">1380</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Wang, Y.</author><author>Su, H. H.</author><author>Yang, Y.</author><author>Hu, Y.</author><author>Zhang, L.</author><author>Blancafort, P.</author><author>Huang, L.</author></authors></contributors><auth-address>Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.</auth-address><titles><title>Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy</title><secondary-title>Mol Ther</secondary-title></titles><periodical><full-title>Mol Ther</full-title></periodical><pages>358-67</pages><volume>21</volume><number>2</number><keywords><keyword>CA151652</keyword></keywords><dates><year>2013</year><pub-dates><date>Feb</date></pub-dates></dates><isbn>1525-0024 (Electronic)&#xD;1525-0016 (Linking)</isbn><accession-num>23229091</accession-num><abstract>Failure of clinical trials of nonviral vector-mediated gene therapy arises primarily from either an insufficient transgene expression level or immunostimulation concerns caused by the genetic information carrier (e.g., bacteria-generated, double-stranded DNA (dsDNA)). Neither of these issues could be addressed through engineering-sophisticated gene delivery vehicles. Therefore, we propose a systemic delivery of chemically modified messenger RNA (mRNA) as an alternative to plasmid DNA (pDNA) in cancer gene therapy. Modified mRNA evaded recognition by the innate immune system and was less immunostimulating than dsDNA or regular mRNA. Moreover, the cytoplasmic delivery of mRNA circumvented the nuclear envelope, which resulted in a higher gene expression level. When formulated in the nanoparticle formulation liposome-protamine-RNA (LPR), modified mRNA showed increased nuclease tolerance and was more effectively taken up by tumor cells after systemic administration. The use of LPR resulted in a substantial increase of the gene expression level compared with the equivalent pDNA in the human lung cancer NCI-H460 carcinoma. In a therapeutic model, when modified mRNA encoding herpes simplex virus 1-thymidine kinase (HSV1-tk) was systemically delivered to H460 xenograft-bearing nude mice, it was significantly more effective in suppressing tumor growth than pDNA.</abstract><notes>CA125273/CA/NCI NIH HHS/United States&#xD;CA125273-03S1/CA/NCI NIH HHS/United States&#xD;CA129835/CA/NCI NIH HHS/United States&#xD;CA149363/CA/NCI NIH HHS/United States&#xD;CA151652/CA/NCI NIH HHS/United States&#xD;R01 CA129835/CA/NCI NIH HHS/United States&#xD;R01 CA149363/CA/NCI NIH HHS/United States&#xD;Journal Article&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;United States&#xD;the journal of the American Society of Gene Therapy</notes><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=23229091 </url></related-urls></urls><language>eng</language></record></records></xml>